Introduction
The high genetic variability of the human immunodeficiency virus type 1 (HIV-1) and the tendency to persist in hidden viral reservoir have seriously hampered the development of safe and effective vaccines (reviewed in Ref. [1] [2] [3] [4] [5] ). More so Lifelong highly active anti-retroviral therapy (HAART) is limited by the continuous emergence of drug resistance and is not curative (reviewed in Ref. [6] ). Since they can selectively kill virus producing cells the induction of potent HIV-1 specific T cell immunity as a component of prophylactic or therapeutic vaccine remains a highly desired objective ( [7, 8] reviewed in Ref. [1] ). The presence of robust multifunctional T cell immunity for example has been associated with long term viremia suppression of HIV-1 in Elite controller ( [9, 10] , rev. in Ref. [11] ) and has also been implicated in preclinical studies in the control of pathogenic Simian immunodeficiency virus infections [12, 13] .
Viral vectors are the most efficient vaccine vectors and are being actively optimized for immunization against infectious diseases and cancers (rev. in Ref. [14] ). Unfortunately several clinical evaluation of viral vectored HIV-1 vaccines in multiple heterologous prime boost combinations have yielded limited success [15] [16] [17] [18] . In addition to the poor immunogenicity of some of these vaccine candidates a major obstacle has been pre-existing or the risk of the induction of anti-vector immunity during the course of immunization [19, 20] . We previously reported that preprograming of helper CD4 þ T cells using dendritic cells targeted proteinbased vaccine enables DNA vaccines to be more immunogenic in mice [22] . One component of the improved protection was a more rapid accumulation of gag-specific CD8 þ T cells to a mucosal infection challenge site. Previously to improve viral vectored HIV-1 gag vaccine we targeted the encoded antigen to dendritic cells in situ using either adenoviral or rNDV vectored HIV-1 vaccine leading in enhanced T cell immunity [21] . In this study we have demonstrated that successive administration of anti-DEC205-gagP24 protein plus polyICLC and rNDV-L-gag vaccines results to vigorous systemic and mucosal T cell immunity. Here antigen specific helper CD4 þ T cells are elicited by a priming dose of a DEC-targeted protein vaccine which then improves the induction of T cell immunity by a rNDV-L-gag vaccine. In addition to an enhanced T cell immunity; this approach strongly amplified persistent CD8 þ T cells in murine airway and improved protection against airway challenge with a recombinant vaccinia gag virus. To the best of our knowledge, this is the first viral vectoreddendritic cell targeted protein vaccine combination strategy in mice in which the concept of helper CD4 þ T cells has been exploited not only to direct the induction of a balanced HIV-1 gag specific T cell immunity but equally to intentionally focus protective CD8 þ T cell responses at the site of pathogenic virus challenge. In contrast to our previous findings on complementary prime boost vaccination where a more rapid accumulation of gag-specific CD8 þ T cells occurred upon pathogenic virus challenge, here enhanced accumulation of vaccine induced T cells to the lungs is driven by mucosal rNDV-L-gag application. We previously used the term ''complementary'' prime boost to describe a DEC-gag prime plus DNA boost [22] . Here we extend this concept to include DEC-gag prime plus rNDV-L-gag boost where an anti-DEC205-gagP24 plus polyICLC protein vaccine is combined with viral vectored vaccine to enhance protective T cell immunity in murine airway.
Materials and Methods

Mice and rNDV-L-gag vaccination
CxB6 F1 mice from Harlan were maintained under specific-pathogen free conditions and used at 6-10 weeks under the guidance of the Rockefeller University Institutional Animal Care and Use Committee. Mice were inoculated with rNDV-L-gag or rNDV-L-GFP intranasally as previously reported [21] . The mice were anesthetized with Halothane. On the other hand DEC-gag plus polyICLC injection was given subcutaneously in the paws as previously reported [22, 23] .
Ethical statement
Mice were maintained under specific-pathogen free conditions and used at 6-10 weeks under the guidance of the Rockefeller University Institutional Animal Care and Use Committee.
Cell lines, media, and antibodies
A 293 T (293ts/A1609), CHOneo cells, and CHOmDEC205 cell lines were maintained in DMEM supplemented with 5% FCS, penicillin, streptomycin and glutamine. CV-1 cells were maintained in this medium but with geneticin in place of streptomycin. Antibodies to CD3, CD4, CD8a, and cytokines (IFN-g, IL-2, and TNF-a) were purchased from BD Biosciences-Pharmingen, San Jose, CA. Other antibodies were from Beckman coulter including FITC labeled (KC57-FITC; Coulter) or HRP-conjugated antibody (ImmunoDiagnostics, Woburn, MA) to HIV gag p24 and HIV gag CD8 þ tetramer (AMQMLKETI) H-2Kd PE.
Fusion HIV-1 gag mAbs These were generated as described [24, 25] . SDS/PAGE was used to assess the quality of the anti-DEC-gagP24 (DEC-gag) fusion proteins, while western blotting using HRP-anti-p24 (ImmunoDiagnostics) was used to determine the specificity of the gag fusion constructs. mAb binding was verified on CHO cells stably transfected with the mouse DEC-205 by FACS, using either PE-conjugated goat anti-mouse IgG (Jackson ImmunoResearch, West grove, PA) or FITCconjugated anti-p24 (KC57-FITC, coulter). All mAbs were endotoxin-free in limulus Amebocyte Lysate assay, QCL-1000 (Cambrex, Walkersville, MD).
15-mer peptide libraries
Overlapping (staggered by 4 aa) 15-mer peptides spanning the entire HIV-1 gag p24 [25] were synthesized by the proteomic Resource Center (The Rockefeller University). The resuspension had previously been reported in [22, 23, 25] .
Immunizations
Female CXB6 F1 mice were injected once subcutaneously as described above with 5ug DEC-gag together with poly-ICLC (50 mg Oncovir, NW Washington, DC) as adjuvant. 4 wks later the mice received either a boost with 1 Â 10 6 rNDV-Lgag i.n. or a second dose of 5ug DEC-gag plus 50 ug poly-ICLC subcutaneously Polyinosinic-polycytidylic acid-polylysine-carboxymethylcellulose (poly-ICLC, Hiltonol; Oncovir, Washington, DC, USA) is a stabilized double-stranded RNA (dsRNA).
Assays for HIV-specific immune T cells
To determine the breadth of HIV-1 gag-specific T cell responses, bulk splenocytes were restimulated in vitro either with peptides mix spanning the entire gagP24 protein [24, 25] or a negative unreactive control peptide mix consisting of HIV-1 nef pool mix in the presence of 2 mg/ml of anti-CD28 (clone 37.51) for 6 h, adding 10 ug/ml brefeldin A (SigmaAldrich, St. Louis, MO) for the last 4 h to accumulate intracellular cytokines. Dead cells were excluded using live/ dead fixable dead stain kit (Aqua live/dead; Invitrogen). After blocking Fcg receptors, the cells were stained with antibodies to CD3-pacific blue, CD4-percp, CD8-alexa-750, and Aqua live/dead stain for 20 min at 378C. Cells were washed, fixed (Cytofix/cytoperm; BD Bioscience), permeabilized with Permwash and stained with antibodies to IFNg (IFNgalexa-700), IL-2 (IL-2-FITC), and TNF-a (TNF-a-PE-CY7) for 15 min at room temperature. All antibodies were from Ebioscience. We use BD LSRII for acquisition with data analysis in Flowjo (Tree Star, Inc).
HIV-1 gag CD8
þ tetramer staining
Lymphocytes were washed once with PBS and stained with HIV-1 gag CD8 tetramer (AMQMLKETI) H-2Kd PE, CD3-pacific blue, CD4-percp, CD8-alexa-700, and Aqua live/dead for 20 min at 48C as previously described [22, 24] .
Vaccinia gag protection assays
Nembutal-anesthetized mice were challenged with 10 5 PFU/ mouse of infectious recombinant vaccinia gag virus by the intranasal route, in 35 ml PBS with Mg/Ca. The negative controls were wild type vaccinia virus, Vaccinia-luciferase or vaccinia-OVA virus. The weight of each animal (groups of 5) was determined daily for 7 days following challenge. Then mice were euthanized, the lungs were harvested and homogenized in transport medium (0.1% gelatin in PBS), and stored in duplicates at À808C prior to virus titration. Lung virus titers of individual mice in each group were determined by plaque assay on monolayers of CV-1 cells as described [21] [22] [23] [24] [25] [26] .
CD8þ and CD4þ T cell depletion
Vaccinated animals were depleted of CD8þ T-cells, by injection 150 mg of anti-CD8 antibody (clone 2.43) at day À2, À1, and 0 before challenge. In the depletion of CD4 T cells 200 mg of anti-CD4 antibody (clone GK.1.5) similarly injected during the same time interval. To deplete both CD4þ and CD8þ T cells vaccinated mice were treated a combination of 100ug of each depletion antibody. A normal rat IgG (200 mg per mouse) was injected in a control group. The effectiveness of the depletion was assessed at day 0 prior to the challenge through staining for T cells in the lungs and spleen.
Statistics
Post challenge mean Vaccinia virus lung titers and mean percentage in weight loss were compared between vaccination groups using two tailed Student's t test. Differences were considered significant at p < 0.05 after analysis using prism 6 Graph Pad Software. Similarly differences in mean total tetramer binding CD8 þ T cells
were also compared using two tailed student's Test.
Results
Complementary prime boost vaccination with DC targeted gag protein vaccine and rNDV-L-gag enhances protective immunity to airway challenge with vaccinia gag
We previously demonstrated that a complementary prime boost with DC-targeted HIV-1 gag protein vaccine and DNA enhances protective CD4 þ /CD8 þ T cell immunity to airway challenge with a high dose of recombinant vaccinia gag virus [22] . Here we extend this concept to include the enhancement of protection afforded by combining a DCtargeted gag protein vaccine prime and rNDV-L-gag boost.
To test the protection afforded by protein and rNDV-L-gag vaccines, we first compared two doses of DC-targeted, DECgag protein vaccine to two doses of rNDV-L-gag vaccine, given 1 month apart in a homologous prime boost approach, and challenged 12 weeks later with a lethal intranasal dose of recombinant vaccinia-gag virus. Weight loss was monitored daily and at days 6-7, the mice were euthanized and lung virus titers determined as previously described [22] [23] [24] [25] 27] . Both protein and rNDV-L-gag forms of vaccine in a homologous prime boost vaccination resulted to 2-2.5 log fold less lung virus than the na€ ıve mice (Fig. 1b) . Next, to try to improve protective immunity, we immunized mice sequentially with a single dose of DECtargeted gag protein vaccine followed by an intranasal boost with rNDV-L-gag 4 weeks later. Twelve weeks after boosting, mice were challenged with a recombinant vaccinia gag, where upon weight loss was monitored daily and lung virus titers determined as described in the Section Vaccinia-gag protection assay. All mice lost weight during the first three days post challenge. However mice receiving either DECempty or rNDV-L-gfp (control vaccines without gag) showed continuous weight loss. A single dose of rNDV-Lgag vaccine did not protect against weight loss (Fig. 1a) . Mice receiving two doses of either DEC-gag or rNDV-L-gag exhibited some protection against weight loss. However, priming with DEC-gag plus polyICLC protein vaccine followed by a rNDV-L-gag boost provided superior protection against weight loss to either two rNDV-L-gag or DEC-gag vaccines (Fig. 1a) and reduced lung virus titers by an average of 5 logs in 4 experiments (Fig. 1b) , which titers were significantly lower than mice receiving a homologous prime boost vaccine (p < 0.02). The control for the challenge experiment were three viruses including wild type vaccinia virus with no insert (Vaccinia WT), recombinant vaccinia-luciferase and recombinant Vaccinia-OVA ( Figure S1 ).
CD4
þ and CD8 þ T cells protect mice after DEC-gag protein-prime rNDV-L-gag-boost vaccine Female CxB6 F1 Mice vaccinated as indicated in the x-axis of Figure 2 were treated either with control rat IgG (a) or depleting antibodies to aCD4, aCD8, or both (aCD4&aCD8) at days À3, À2, À1 prior to airway challenge with recombinant vaccinia-gag virus. Lung virus titer (PFU/lung) was determined 7 days after as previously described [21] [22] [23] [24] [25] [26] .
Generally a depletion of both CD4 þ and CD8 þ T cells abrogated protection completely in all vaccine treated groups (Fig. 2d) . In Figure 2b and c the depletion of 
CPB with DC targeted gag protein vaccine and rNDV-L-gag results to rapid and durable gag reactive CD8 þ T cells in murine airway
We previously demonstrated that pre-programming of helper CD4 þ T cells by dendritic cell targeted HIV gag protein plus polyICLC (DEC-gag) vaccination helped DNA vaccines improve the mobilization of protective CD8 þ T cells in murine airway [22] . Since rNDV-L-gag is administered via the intranasal route we tested whether DEC-gag vaccine can also improve rNDV-L-gag induced CD8 þ T cell response in murine airway. Briefly female 6-8 weeks old CXB6 F1 mice were vaccinated twice at 4 weeks apart as indicated in Figure 3b . We then asked whether the priming with DEC-gag vaccine improved CD8 þ T cell responses by examining the rapidity with which gag-specific CD8 þ T cells were mobilized quantitatively to a site of infection. In four experiments, 30 days after DEC-gag vaccination, we boosted the mice with rNDV-L-gag i.n. and then examined the site of infection, the lungs, as well as the spleen 7 and 50 days later. Priming with DEC-gagP24 plus polyICLC followed by boosting with one dose of rNDV-L-gag led to a rapid and better accumulation of CD8 þ T cells to the lung (p ¼ 0.05) within 7 days than a single dose or 2 doses of rNDV-L-gag vaccine (compares Fig. 3b rows II, III, &V). Seven days after DEC-gag prime followed by rNDV-L-gag boost CD8
þ T cell immunity in the lungs increased 8.5 fold relative to 2x rNDV-L-gag vaccination. When monitored over time the CD8 þ T cell responses persisted for well over 50 days increasing over time in both the spleen and lungs ( Fig. 3d and e) . When compared with the spleen CD8 þ T cell accumulation in the lungs was at least three fold higher than the spleen after complementary prime boost vaccination (compare Fig. 3d and e). Homologous vaccination with 2x DEC-gagP24 plus poly-ICLC produced no gag specific CD8 þ T cell responses as previously reported [23] . To establish that the accumulation of gag-reactive CD8 þ T cells in the lungs and spleen was specific to the vaccine antigen we next vaccinated mice twice with DEC-gag protein plus polyICLC then boosted with NDV-L-GFP. In the absence of gag within the rNDV vector no gag specific tetramer binding CD8 þ T cells were detected clearly indicating that GFP as an irrelevant antigen has no effect in mobilizing HIV-1 gag reactive CD8 þ T cell. This is also a control to show that the rNDV vector on its own is not responsible for the expansion of preexisting antigen specific T cells. Thus complementary DEC-gag prime-rNDV-L-gag boost enables a rapid and durable mobilization of CD8 þ T cells in murine airway.
DC-targeted protein vaccination results to strong combined CD4 þ and CD8 þ T cell immunity to an rNDV-L-gag vaccine
To assess T cell immunity after vaccination with dendritic cell targeted gag protein followed by a rNDV-L-gag boost, we measured CD4 þ and CD8 þ , gag-specific T cells at the single When mice vaccinated twice with DC targeted protein plus polyICLC are boosted with NDV-L-GFP only CD4 þ T cell specific to the gag protein are detected clearly indicating that GFP as an irrelevant antigen would not boost preprogramed gag specific T cells. This is also a control to show that the NDV vector on its own is not responsible for the expansion of pre-existing antigen specific T cells. On the other hand prior vaccination with DC targeted protein resulted in strong combined CD4 þ and CD8þ T cells immunity to a single dose of NDV-L-gag ( Fig. 4a-d , compare rows VI). Thus complementary prime boost enables a balanced induction of both CD4 þ and CD8 þ T cells ( Figure S2 ).
CPB with DC targeted gag protein vaccine and rNDV-L-gag elicits durable polyfunctional T cells
T cells producing multiple cytokines appear to be especially effective in protective immunity [9, [28] [29] [30] [31] and have been associated with long term control of HIV-1 in elite controllers. We therefore examined the quality of the T cell responses induced by complementary DC targeted protein and rNDV-L-gag vaccination in terms of the ability of the gag specific T cells to secrete multiple cytokines such as 
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IFNg, TNF-a, and IL-2 (polyfunctional T cells) . Briefly female CxB6 F1 mice were vaccinated as described above and the gag specific T cells were assessed at the single cell level for their ability to secrete multiple cytokines such as IFNg, TNFa, and IL-2 (Fig. 5) . In four separate experiments seven days after immunization complementary DC targeted gag and rNDV-L-gag vaccination enabled the induction of triple cytokine secreting cells (including IFNg, IL-2, and TNF-a)
by both CD4 and CD8 T cells (Fig. 5a and b) . Particularly in the CD8 þ T cell compartment cytokine formation after CPB vaccination was significantly higher (p < 0.003) than immunization with 2x NDV-L-gag.
As previously reported homologous vaccination with 2x DEC-gag plus polyICLC vaccination resulted to strong polyfunctional T cell responses only in the CD4 þ compartment with no detectable gag specific polyfunctional CD8 þ T Figure 2 . CD4 þ and CD8 þ T cells protect mice after DEC-gag protein-prime rNDV-L-gag-boost vaccine. Mice vaccinated as indicated in x-axis of Figure 3 (a-d) above were treated as indicated with control rat IgG or depleting antibodies to aCD4, aCD8, or both (aCD4 & aCD8) at days À3, À2, À1 prior to airway challenge with recombinant vaccinia-gag virus. Lung virus titer (PFU/lung) was determined 7 days after challenge with recombinant vaccinia-gag virus (Mean AE SD of three repeat experiments) (ns, not significant (two tailed student's t test).
cells [22, 23, 25] . As shown in Figure 5a more double cytokine forming cells were also detected in gag specific CD4 þ T cells than in the CD8 compartment. When monitored 50d later multiple cytokine forming cells persisted in both the CD4 þ and CD8 þ compartment ( Fig. 5c and d) . Thus CPB provides improved systemic CD4 þ and CD8 þ T cell immunity to one dose of rNDV-Lgag vaccine. 
Discussion
In this study, we demonstrate that successive administration of DEC-gag protein and rNDV-L-gag vaccines results to vigorous systemic and mucosal T cell immunity. Here antigen specific helper CD4 þ T cells are elicited by a priming dose of a DEC-targeted protein vaccine which then improves the induction of T cell immunity in murine airway by an rNDV-L-gag vaccine. In addition to an enhanced T cell immunity; this approach strongly amplified persistent polyfunctional T cells in the vaccinees and improved protection against airway challenge with a recombinant vaccinia gag virus. To the best of our knowledge, this is the first viral vectored vaccine strategy in mice where by the concept of helper CD4 þ T cells has been exploited not only to direct the induction of a balanced HIV-1 gag specific T cell immunity but equally to intentionally focus broadly reactive T cell responses at the site of pathogenic virus challenge. This approach as previously reported in our group for DNA vaccines [22] is termed complementary prime boost vaccination because two vaccines inducing different types of immunity are combined together to achieve effective immunization. This concept is now extended here to include directing mucosal viral vectored vaccine with helper CD4
þ T cells to focus T cell immunity at pathogenic virus entry points. However unlike our previous report where initially the was lesser vaccine specific T cells in the lungs vis a vis spleen [22, 32] following complementary DEC-gag prime-rNDV-L-gag vaccine boost at least 3 to 8 fold more long lasting tetramer binding CD8 þ T cells are induced in the lungs than the spleen. In the context of HIV-1 infection robust multifunctional mucosal T cells would be vital not only in abrogating infection but equally in limiting HIV-1 viral reservoirs establishment through active killing of virus producing cells [7, 8, [33] [34] [35] . Multiple vaccine combination strategies have been exploited to augment viral vectored vaccines mediated T cell immunity (reviewed in Ref. [36] [37] [38] [39] [40] [41] ), including heterologous vector prime protein boost or vice versa [42] [43] [44] . However in CPB we emphasize combining dendritic cell targeted antigen vaccination with other conventional approaches because it intensifies and broadens antigen specific immune responses [22, 23, [45] [46] [47] [48] [49] [50] . Here coordinated cellular interplay between DC, CD4, CD8, B, and probably other immune cells is critical not only in shaping the quantity or quality of the vaccine mediated immune responses but also in the ultimate protection from pathogenic viral challenge. Synthetic double-stranded RNA, polyICLC, for example, is necessary to activate DC loaded with HIV-1 gag to induce broadly reactive helper CD4 þ T cells as previously reported in our group [22, 23, 25, 49, 51] . During this process IFNAR signaling in DC after polyICLC stimulation has recently been demonstrated [51] to be a pre-requisite for the effective induction of CD4 þ and CD8 þ T cells. In addition evidence also indicates that this signaling activates all path ways necessary for immune induction and also reprograms DC metabolism for effective immune induction [50, 52] . On the other hand the contribution of CD4 þ T cells to the CPB strategy are numerous including our previous report [22] and several other findings demonstrating the usefulness of helper CD4 þ T cells in T cell immunity [22, 32, 43] (reviewed in
Ref. [53, 54] ). The complementary prime boost approach described here, in which DC-targeted protein vaccine favors helper cell formation and rNDV-L-gag vaccine favors mucosal T cell immunity limits repeated vector administration thereby reducing anti-vector immunity as well as competition between peptides presented from vector and vaccine antigens. By directing the helper response to defined proteins, it may be feasible to amplify and improve the quality of the immunity induced by viral vectored vaccines, and augment resistance to infectious and malignant diseases. Nevertheless there is a need to assess the efficacy of this strategy in nonhuman primate models and subsequently in first in clinical trials. 
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